Senzime AB (publ) (STO:SEZI)
3.250
+0.120 (3.83%)
Nov 4, 2026, 5:29 PM CET
Senzime AB Revenue
Senzime AB had revenue of 30.10M SEK in the quarter ending September 30, 2026, with 13.68% growth. This brings the company's total for the last twelve months to 106.35M, up 18.56% year-over-year. In the year 2025, Senzime AB had annual revenue of 104.02M with 77.89% growth. That makes Senzime AB the 36,992nd largest company in the world by revenue and 491st in Sweden.
Revenue (ttm)
106.35M
Revenue Growth
+18.56%
P/S Ratio
4.80
Revenue / Employee
1.80M
Employees
59
Market Cap
510.95M
Revenue by Geography
- USA 71.28M 68.5%
- Asia 16.61M 16.0%
- Europe/ Oceania 14.28M 13.7%
- Sweden 1.49M 1.4%
- Central-south America 355.00K 0.3%
Fiscal year ended Dec 31, 2025 See the full Senzime AB breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 104.02M | 45.55M | 77.89% |
| Dec 31, 2024 | 58.48M | 22.72M | 63.55% |
| Dec 31, 2023 | 35.75M | 21.72M | 154.77% |
| Dec 31, 2022 | 14.03M | 3.05M | 27.81% |
| Dec 31, 2021 | 10.98M | 1.64M | 17.60% |
| Dec 31, 2020 | 9.34M | 2.63M | 39.13% |
| Dec 31, 2019 | 6.71M | 3.50M | 108.81% |
| Dec 31, 2018 | 3.21M | 3.03M | 1,600.53% |
| Dec 31, 2017 | 189.00K | -1.44M | -88.39% |
| Dec 31, 2016 | 1.63M | 1.48M | 964.05% |
| Dec 31, 2015 | 153.00K | -388.16K | -71.73% |
| Dec 31, 2014 | 541.16K | -693.86K | -56.18% |
| Dec 31, 2013 | 1.24M | 230.96K | 23.00% |
| Dec 31, 2012 | 1.00M | -813.40K | -44.75% |
| Dec 31, 2011 | 1.82M | 107.76K | 6.30% |
| Dec 31, 2010 | 1.71M | 23.87K | 1.42% |
| Dec 31, 2009 | 1.69M | -666.11K | -28.32% |
| Aug 31, 2007 | 2.35M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| C-Rad AB | 417.60M |
| Mentice AB | 303.13M |
| Devyser Diagnostics AB | 253.60M |
| Bactiguard Holding AB | 216.59M |
| Sedana Medical AB | 198.44M |
| OssDsign AB | 163.80M |
| BrainCool AB | 46.49M |
| Ortoma AB | 33.90M |
Senzime AB News
- 6 days ago - Senzime AB Quarterly report: Q3 2026 - Filings
- 6 days ago - Senzime AB Slides: Q3 2026 - Filings
- 18 days ago - New Scientific Evidence Presented at ANESTHESIOLOGY 2026 Strengthens the Case for Senzime's TetraGraph and Quantitative Neuromuscular Monitoring - Accesswire
- 22 days ago - Senzime Launches Industry-First Predictive Neuromuscular Monitoring Technology - Accesswire
- 4 weeks ago - Senzime Reaffirms Its Target of Reaching Positive Cash Flow Within Q4 2026 - Accesswire
- 5 weeks ago - Senzime Strengthens Financing to Support Strategic OEM Expansion and Path to Profitability - Accesswire
- 5 weeks ago - Senzime Secures Additional Major US Hospital Network Contract, Expanding Adoption of its Next-generation Neuromuscular Monitoring Technology - Accesswire
- 3 months ago - Senzime Awarded Exclusive 5-Year National Supply Contract with U.S. Veterans Affairs Through Its Partner TrillaMed - Accesswire